Antibe Therapeutics Inc.
ATE
Rang in Aktien
#31900
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Aktienkurs
$0.21483059
Zuletzt synchronisiert: 2024-05-07
Marktkapitalisierung
$11.13M
Veränderung (1 Tag)
0.34%
Veränderung (1 Jahr)
-0.36%
Land
CA
Handel Antibe Therapeutics Inc. (ATE)
Kategorie
Healthcare
P/S-Verhältnis für Antibe Therapeutics Inc. (ATE)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Antibe Therapeutics Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Antibe Therapeutics Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| Nicht genügend Daten für die angegebenen Daten. | ||
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 3.82 | - |
US
|
|
| 2.78 | - |
IE
|
|
| 4.18 | - |
US
|
|
| 2.97 | - |
US
|
|
| - | - |
DE
|
